Global High-Priority Regulatory Events — March 09, 2026

09-03-2026

Aureus Greenway Holdings Inc. (AGH) entered into an Agreement and Plan of Merger dated March 8, 2026, with Autonomous Power Corporation, Aureus Merger Sub Inc., and Andrew Fox as Stockholder Representative, under which AGH's wholly-owned subsidiary will merge with Autonomous Power, surviving as a wholly-owned subsidiary of AGH. The Parent Board and Company Board unanimously approved the transaction, with requisite stockholder consents to be delivered promptly, and the merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Code. AGH will amend its charter to change its name to Powerus Corporation effective at closing.

• ·Filing Date: March 09, 2026
• ·Agreement Date: March 8, 2026
• ·Closing to occur on second Business Day after satisfaction of conditions in Article VI
• ·Simultaneous execution of Lock-Up Agreements (Exhibit A) by Company Significant Holders and Leak-Out Agreements (Exhibit B) by Parent Significant Holders, effective at Closing
• ·Parent name change to Powerus Corporation via Parent Charter Amendment

09-03-2026

Netlist, Inc. entered into the First Amendment to Lease with University Research Park LLC, dated March 4, 2026, as reported in this 8-K filing under Item 1.01 (Entry into a Material Definitive Agreement). The amendment is attached as Exhibit 10.1. The filing was signed by Gail M. Sasaki, Executive Vice President and Chief Financial Officer, on March 9, 2026.

09-03-2026

Responsive Industries Limited issued a revised disclosure on March 9, 2026, correcting a typo in the prior filing regarding pledge creation by promoter group entity Fairpoint Tradecom LLP on March 5, 2026, for personal borrowings to Virtu Financial Services Limited and Imperial Solutions Private Limited. Fairpoint Tradecom LLP holds 24,650,000 shares (9.25% of total share capital), with total encumbered shares increasing to 40,99,971 (14.20%). No financial impact or release details provided.

• ·Original disclosure dated March 7, 2026, contained a typo error in pledge details.
• ·Date of reporting to exchanges: March 6, 2026.
• ·Pledge created for personal borrowings.

09-03-2026

RBI released money market operations data as on March 07, 2026, showing overnight segment volume of ₹14,032 Cr at a weighted average rate of 4.95% (range 4.00-5.15%), with triparty repo dominating at ₹8,590 Cr. RBI's LAF operations resulted in net liquidity absorption of ₹338,238 Cr on that day, contributing to an overall net liquidity absorption of ₹247,279 Cr including outstanding operations. Scheduled commercial banks' cash balances with RBI were ₹746,981 Cr, slightly below the average daily CRR requirement of ₹763,554 Cr for the fortnight ending March 15, 2026.

• ·Call money volume: ₹1,071 Cr at 4.76% (range 4.60-5.15%)
• ·Term market repo volume: ₹625 Cr at 1.00%
• ·Net liquidity from outstanding operations: +₹90,959 Cr (injection)
• ·Standing Liquidity Facility (SLF) availed: ₹7,418 Cr
• ·Net durable liquidity surplus as on February 15, 2026: ₹5,60,171 Cr
• ·Government of India surplus cash balance as on March 06, 2026: ₹0 Cr

09-03-2026

Adani Enterprises Limited incorporated a wholly owned subsidiary, CORR Tollways Limited (CTL), on March 9, 2026, in India, with an authorized and paid-up capital of ₹10 L. CTL will focus on tolling, operations, and maintenance of Chennai Outer Ring Road (CORR) Phase I (Vandalur to Nemilichery) and Phase II (Nemilichery to Minjur in TPP Road) under concession from Tamil Nadu State Highways Authority (TANSHA). The subsidiary holds 100% shareholding by the Company, subscribed at face value.

• ·Incorporation confirmation received on March 9, 2026 at 12:49 PM
• ·Scrip Codes: BSE 512599, NSE ADANIENT
• ·CIN: L51100GJ1993PLC019067
• ·Cash consideration at face value of ₹10 per share

09-03-2026

Life Insurance Corporation of India received a GST demand order dated March 09, 2026, from the Deputy Commissioner State Taxes and Excise, Parwanoo, Himachal Pradesh, for FY 2019-20 on non-reversal of ITC on exempted supply, comprising GST ₹17.91L, interest ₹27.22L, and penalty ₹17.91L (total ₹63.04L). The order is appealable to the Commissioner (Appeals), Shimla. The Corporation states there is no material impact on its financials, operations, or other activities.

• ·Reference No.: LIC/SE/2025-26/147
• ·Violation: Non-Reversal of ITC on Exempted Supply
• ·Scrip Codes: BSE 543526, NSE LICI

09-03-2026

Unitech International Ltd disclosed outcomes from its 6th Committee of Creditors (CoC) meeting held on March 2, 2026, via video conferencing, where appointments of legal counsel and PCS firm for CIRP compliances, along with ratification of RP expenses, were deferred due to paucity of time. However, the addendum to Form G issued on January 17, 2026, was approved unanimously with 100% voting rights. This is reported under SEBI LODR Regulation 30 as material information during CIRP.

• ·Meeting held at 04:00 P.M. through Video Conferencing
• ·IBBI Registration Number: IBBI/IPA-002/IP-N00828/2019-2020/12629
• ·AFA Valid Till: 30.06.2026

09-03-2026

Product revenue grew significantly to $72.2M from $7.3M YoY while supply agreement revenue increased substantially, but total revenue declined 5% YoY to $84.3M due to an 88% drop in collaboration revenue to $9.7M. Operating expenses surged 186% to $263.7M, driven by a 221% rise in SG&A to $230.1M, leading to a net loss of $171.3M versus $8.0M profit in 2024. Stockholders' equity fell to $114.3M from $256.8M amid heavy operating cash use of $170.9M.

• ·Net cash used in operating activities: $170.9M in 2025 vs provided $13.5M in 2024.
• ·Cash and equivalents decreased by $9.5M net in 2025.
• ·Total assets: $327.7M at Dec 31 2025 (down from $351.2M).
• ·Accumulated deficit: $294.6M at Dec 31 2025 (up from $123.3M).
• ·Term loans, net: $96.4M at Dec 31 2025 (none in 2024).
• ·Auditor focus: rebates estimation as key audit matter.

09-03-2026

PharmaCyte Biotech, Inc. (PMCB) filed a DEF 14A proxy statement on March 9, 2026, for its virtual annual stockholder meeting on March 30, 2026, at 11:00 a.m. ET, with record date January 30, 2026. As of the record date, 10,735,649 common shares were outstanding, plus 2,677,093 as-converted votes from Series C Preferred Stock. The filing includes pay versus performance disclosures for executives Joshua N. Silverman and Kenneth L. Waggoner covering fiscal years ended April 30, 2023, 2024, and 2025, though specific compensation values are not detailed in the provided content.

• ·Annual meeting held virtually; access via http://www.web.viewproxy.com/PMCB/2026
• ·Fiscal year end: April 30
• ·Transfer agent: Equiniti Trust Company, LLC
• ·Business address: 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169

09-03-2026

American Resources Corporation (AREC) filed its 2026 DEF 14A Proxy Statement for the Annual Shareholder Meeting on April 15, 2026, seeking shareholder approval to elect its five current director nominees for one-year terms and to ratify GreenGrowth CPAs as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is February 17, 2026, with 106,925,819 shares of common stock outstanding. The Board unanimously recommends voting FOR both proposals, with no financial performance metrics or period-over-period comparisons disclosed in the filing.

• ·Annual Meeting location: 12115 Visionary Way, Suite 174, Fishers, Indiana 46038; in-person only, no virtual participation option.
• ·Board Diversity (as of January 1, 2026): 1 female, 4 male directors; 1 Hispanic or Latinx director.
• ·Voting methods: Internet at www.AALvote.com/AREC or www.FCRvote.com/AREC, telephone at 1-866-804-9619, mail, or in-person.
• ·Directors elected by plurality vote; abstentions and broker non-votes do not affect outcome.

09-03-2026

Innovation Beverage Group Limited filed a preliminary F-1 registration statement on March 9, 2026, for a proposed public offering of up to $15,000,000 through up to 4,166,667 Ordinary Units (each consisting of one Ordinary Share, one Series A Warrant, and one Series B Warrant) or Pre-Funded Units, with Aegis Capital Corp. as placement agent. The prospectus incorporates prior filings including Form 8-A from September 16, 2024, and details historical unregistered securities issuances from 2023-2024 totaling various small share grants and private placements exempt under Sections 4(a)(2), Reg D, Reg S, and Rule 701. No financial performance metrics or period-over-period comparisons are provided in this filing.

• ·Historical unregistered issuances include a 5:1 share consolidation in 2025 affecting share counts.
• ·F-1 amendments filed multiple times from February 28, 2025, through February 24, 2026.
• ·Company address: 29 Anvil Road, Seven Hills, NSW 2147, Australia.

09-03-2026

This Rule 425 filing by Nuveen Municipal High Income Opportunity Fund (NMZ) is a proxy solicitation urging shareholders of the subject company, Nuveen New Jersey Quality Municipal Income Fund, to vote 'FOR' all proposals ahead of the shareholder meeting on March 19, 2026, to ensure quorum and avoid adjournments. The Board recommends approval of the proposals detailed in the proxy statement, with voting assistance offered via phone by Computershare. No financial metrics or performance data are disclosed in this communication.

• ·Shareholder meeting date: Thursday, March 19, 2026
• ·Voting hours: Weekdays 9:00am until 11:00pm ET; Saturdays Noon to 6:00pm ET
• ·Contact address: 51 West 52nd Street, 6th Floor, New York, NY 10019

09-03-2026

On March 6, 2026, Phillips 66's Board of Directors increased its size from 14 to 16 members and appointed Kevin O. Meyers (age 72) and Howard I. Ungerleider (age 57) as independent directors, effective immediately. Meyers was assigned to the class expiring in 2027 and Ungerleider to the class expiring in 2026; both joined the Audit & Finance Committee and Public Policy and Sustainability Committee. In connection, Grace Puma Whiteford was reclassified as a Class I director with term expiring in 2028.

• ·No arrangements or understandings for appointments; no material interests under Item 404(a) of Regulation S-K.
• ·Pro-rated compensation per standard non-employee director arrangements described in April 8, 2025 proxy statement.

09-03-2026

Pantages Capital Acquisition Corp, a blank check company, reported total assets of $90.4M as of Dec 31, 2025, up from $87.2M prior year, driven by growth in the Trust Account to $90.1M (+4.1%) from interest income of $3.6M. However, cash declined sharply to $0.19M from $0.53M (-65%), operating losses widened to $1.02M from $0.35M, and shareholders' deficit deepened to $(1.38M) from $(0.36M). Net income turned positive at $2.55M (vs prior loss of $0.09M), primarily from Trust interest, with EPS of $0.23.

• ·Prepaid expenses declined to $87,377 from $122,434.
• ·Accounts payable and accrued expenses decreased to $78,128 from $121,039.
• ·Due to related parties minimal at $294 (down from $33,521).
• ·Basic and diluted EPS for redeemable Class A shares: $0.23 in 2025 vs $(0.03) in 2024.

09-03-2026

Tri-County Financial Group, Inc. reported total assets of $1.6B, up 3.7% YoY, with loans growing 3.0% to $1.3B and net income surging 31.0% to $13.7M driven by 16.8% higher net interest income and 10.2% noninterest income growth. However, nonperforming loans ratio rose to 0.43% from 0.33%, credit loss expense flipped to $0.7M from a $1.3M recovery, and allowance coverage of nonperforming loans declined to 264.9% from 346.9%. Financial ratios improved with ROA at 0.88% (up from 0.68%) and ROE at 9.09% (up from 7.45%), but noninterest expense increased 4.9%.

• ·Return on average assets improved to 0.88% from 0.68%; Return on average equity to 9.09% from 7.45%.
• ·Net interest margin expanded to 3.40% from 2.96%.
• ·Tier 1 leverage capital ratio of subsidiary Bank at 10.51% (up from 10.30%); Risk-based total capital ratio at 14.91% (up from 14.50%).
• ·Mortgage banking income up 13.4% to $11.3M; Insurance services up 24.6%.

09-03-2026

Future Money Acquisition Corporation, a Cayman Islands-incorporated blank check company (SIC 6770), filed Amendment No. 2 to its Form S-1 registration statement (No. 333-291996) on March 6, 2026, as an exhibits-only update with no changes to the main prospectus. New exhibits include specimen unit/share certificates, legal opinions, auditor consents, and a filing fee table, while previously filed exhibits remain unchanged. The filing advances the proposed IPO, with sales to commence as soon as practicable post-effectiveness.

• ·Principal executive offices: 475 Brannan St, San Francisco, CA 94107; Phone: +1 6479860980
• ·Agent for service: Cogency Global Inc., 122 East 42nd Street, 18th Floor, New York, NY 10168
• ·Key exhibit dates: Securities Subscription Agreement (Nov 24, 2025); Promissory Note (Oct 2, 2025, as amended)
• ·Registrant status: Non-accelerated filer, smaller reporting company, emerging growth company
• ·Newly filed exhibits (**): 1.1 (Underwriting Agreement), 4.1 (Unit Cert.), 4.2 (Share Cert.), 5.1 (Harney Opinion), 23.1 (HYYH Consent)

09-03-2026

Cumberland Pharmaceuticals Inc. reported net revenues of $44.5M for the year ended December 31, 2025, up 17.6% YoY from $37.9M, driven by strong growth in Sancuso (+32% to $11.9M), Vibativ (+33% to $9.5M), new Talicia ($3.3M), and Other (+211% to $4.1M). However, Kristalose revenues declined 31% to $10.5M and Caldoror fell 6% to $4.7M; operating loss narrowed to $2.8M from $6.4M but remained negative, with net loss at $2.9M versus $6.4M prior year. Cash and equivalents decreased to $11.4M from $18.0M, working capital dropped sharply to $0.3M from $4.8M, and current ratio slipped to 1.0x from 1.2x.

• ·Cash from operating activities improved to $4.9M in 2025 from -$0.6M in 2024.
• ·Vibativ contribution margin: $7.6M in 2025 vs. $3.6M in 2024.
• ·Sancuso contribution margin: $7.2M in 2025 vs. $4.4M in 2024.
• ·Revolving line of credit availability increased to $9.8M from $4.7M.

09-03-2026

Mobile-health Network Solutions (MNDR), a Cayman Islands-incorporated foreign private issuer operating telemedicine and medical services in Southeast Asia (Singapore, Vietnam, Malaysia, Indonesia), filed a preliminary F-1 registration statement on March 9, 2026, for a proposed IPO. As an emerging growth company, it is exempt from certain stringent executive compensation and other disclosure rules applicable to U.S. domestic issuers. The filing references financial periods ending June 30, 2025, and prior years, along with subsidiaries and intangible assets like the MaNaDr App software, but no specific financial metrics are disclosed in the provided excerpt.

• ·Subsidiaries acquired on specific dates: KlinikKWongSdnBhd (Jul 3, 2024), PTMobileHealthNetworkSolution (Aug 6, 2024), SkylinkInnovationsPteLtd (Nov 27, 2024), MedilinkClinicPteLtd (Jan 13, 2025).
• ·Intangible assets include Patents, MaNaDr App Software, Trademarks, and Software Under Development as of Jun 30, 2025.
• ·Operations in SG, VN, MY, ID for FY ended Jun 30, 2025.

09-03-2026

EVgo Inc.'s 10-K filing highlights operational strategies including efficient charging equipment procurement, technology-enabled products like Autocharge+ and the EVgo Public Network to enhance customer experience and efficiencies, and diversified charging revenue streams from retail, commercial fleets, and OEM partnerships. However, it emphasizes significant risks from evolving regulations such as the OBBBA terminating the 30C income tax credit, potential policy changes, inflation driving up costs, and U.S. tax law modifications that could adversely impact financial condition. These factors underscore a challenging regulatory and economic environment amid efforts to maintain market leadership in EV charging infrastructure.

• ·Filing Date: March 09, 2026
• ·Risks include termination of 30C income tax credit via OBBBA and potential tariff/sanctions changes

09-03-2026

Melar Acquisition Corp. I/Cayman, a blank check company with no operating history or revenues, filed its 10-K on March 9, 2026, for the year ended December 31, 2025, disclosing risks related to completing an initial Business Combination, including the proposed Everli Business Combination which could result in substantially all assets and revenue in a foreign country. The filing details potential Working Capital Loans up to $1.5M from the Sponsor or affiliates, convertible into warrants, and lists beneficial owners via Schedule 13G filings from entities like LMR Partners, AQR, Wolverine (holding 926,328 Public Shares as of Sep 30, 2025), Mizuho, and others. No operating performance metrics are provided, consistent with SPAC status.

• ·Company inception: March 11, 2024
• ·Financial statements compare year ended December 31, 2025 to period from inception through December 31, 2024
• ·Risk of negative interest rates on Trust Account investments potentially reducing per-share redemption value
• ·Schedule 13G filing dates: November 14, 2024 (LMR, AQR); August 14, 2025 (Meteora); October 10, 2025 (Wolverine); November 13, 2025 (Mizuho); February 11, 2026 (W.R. Berkley); March 21, 2025 (Barclays)

09-03-2026

The Nomination and Remuneration Committee of Jagsonpal Pharmaceuticals Limited approved the grant of 11,52,500 employee stock options under the Employees Stock Option Plan, 2022, at an exercise price of ₹139 per option. These options are convertible into an equivalent number of equity shares of ₹2 each and will vest in 4 equal annual tranches commencing from the first anniversary of the grant. The approval was made during a committee meeting on March 09, 2026.

• ·Scrip Code on BSE: 507789; Symbol on NSE: JAGSNPHARM

09-03-2026

SharpLink Gaming reported total revenue of $28.1M for FY 2025, up 666% YoY from $3.7M, driven by $25.6M in new staking revenue, though affiliate marketing revenue declined 33% YoY to $2.5M. The company posted a massive net loss of $734.6M, primarily due to $616.2M unrealized losses on crypto assets and $140.2M impairment on LsETH holdings, contrasting with a $10.1M profit in FY 2024 which included discontinued operations income. LsETH holdings stood at a carrying value of $500.9M (204,409 units) after acquisitions funded by PIPE and ATM offerings, with original cost basis of $624.7M.

• ·ETH traded below $1,472 and above $4,821 per ETH on Coinbase in 2025.
• ·LsETH acquisitions: 236,983 units at approx. average purchase price per LsETH of $3.
• ·Adopted ASU 2023-08 effective Jan 1, 2025 for fair value accounting of ETH holdings.
• ·No long-term debt on balance sheet.
• ·Stock-based compensation, related party: $16.5M in 2025.

09-03-2026

Xanadu Quantum Technologies Inc. announced a $2.0M ARPA-E grant to develop a quantum simulation platform for next-generation batteries, in partnership with the University of Chicago, as part of the QC3 program. This builds momentum ahead of its business combination with Crane Harbor Acquisition Corp., expected to provide $500M in gross proceeds ($225M from trust assuming no redemptions, $275M PIPE), with NewCo listing on Nasdaq and TSX. No financial declines or flat metrics reported; the grant supports a 3-year project targeting 100x faster simulations versus classical methods.

• ·3-year project duration focused on defect formations in battery materials using X-ray absorption spectroscopy and reaction rate algorithms
• ·Project goal: 100x reduction in simulation runtime vs. classical methods
• ·Form F-4 registration statement filed with SEC for the business combination

09-03-2026

Longeveron Inc. reported the immediate resignation of Board member and Audit Committee chairman Richard Kender on March 3, 2026, due to his new role as Executive Chairman and Interim CEO at Seres Therapeutics, resulting in temporary non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) for lacking three independent audit committee members and a financial expert. On March 4, 2026, the company appointed existing Board member Dr. Roger Hajjar to the Audit Committee, restoring the minimum three independent members but still without a financial expert. Longeveron plans to appoint or elect a qualified independent audit committee financial expert within the 180-day cure period or at the next annual shareholders' meeting.

• ·Resignation not due to any disagreement with company operations, policies, practices, management, or Board.
• ·Seres Therapeutics announced Kender's new role on March 2, 2026.

09-03-2026

Mission Produce, Inc. (AVO) filed an S-4 registration statement on March 9, 2026, as a joint proxy statement/prospectus for a proposed two-step merger acquisition of Calavo Growers, Inc., involving wholly-owned subsidiaries Cantaloupe Merger Sub I, Inc. and Cantaloupe Merger Sub II, LLC, pending shareholder approvals at virtual special meetings. As of March 6, 2026, Mission Produce has 70,846,364 shares outstanding (30.85% beneficially owned by directors and executives, who intend to vote in favor), while Calavo has 17,874,079 shares outstanding; however, the filing prominently highlights substantial risks related to the mergers, Mission Produce, Calavo, and the combined company.

• ·Mission Produce Special Meeting to vote on Share Issuance Proposal and Adjournment Proposal; requires majority of voting power present.
• ·Calavo Special Meeting to vote on Merger Agreement Proposal (majority of outstanding shares), Merger-Related Compensation Proposal (majority of shares represented), and Adjournment Proposal.
• ·Calavo engaged Georgeson Advisory as proxy solicitor.

09-03-2026

908 Devices Inc. reported total revenue of $56.2M for the year ended December 31, 2025, up 17.7% YoY from $47.7M in 2024, driven by strong growth in recurring revenue (+22.0% to $19.4M), U.S. state/local sales (+38.2% to $24.2M), rest of world (+21.4% to $14.4M), and global pharmaceutical/industrial (+98.7% to $3.0M). However, U.S. federal and defense revenue declined 13.6% to $14.5M, contract revenue fell 11.4% to $0.1M, and device sales growth slowed to 15.7% at $36.7M, amid risks from long sales cycles and heavy reliance on government contracts.

• ·Over 700 customers including major government institutions.
• ·Risks include long and unpredictable sales cycles, heavy dependence on U.S. government orders, and potential impacts from government contracting/fiscal policy changes.

09-03-2026

Cross Country Healthcare's 2025 revenue declined 21.6% YoY to $1.05B from $1.34B, with Nurse and Allied Staffing revenue dropping to $863M amid 17.3% fewer FTEs (6,784 vs 8,205) and 8.5% lower revenue per FTE/day ($346 vs $378), while Physician Staffing revenue fell slightly to $192M on 14% fewer days filled despite 12.1% higher revenue per day ($2,274 vs $2,029). Net loss widened dramatically to $95M from $15M, driven by $78M impairment charges (up from $3M) and operating loss of $84M (vs $17M). Total assets shrank to $449M from $589M, reflecting significant goodwill impairment.

• ·Cash and equivalents increased to $109M from $82M.
• ·Goodwill decreased to $64M from $135M.
• ·Corporate overhead declined to $61M from $69M.
• ·Contribution income for Physician Staffing rose slightly to $16M from $15M.

09-03-2026

Jhaveri Credits and Capital Limited informed BSE Limited via Regulation 30 that a copy of the NCLT Ahmedabad order on the Scheme of Amalgamation between U R Energy (India) Private Limited (Transferor) and Jhaveri Credits and Capital Limited (Transferee) has been uploaded on the NCLT website. This follows an earlier intimation on March 06, 2026, regarding the reservation of the order under Sections 230-232 of the Companies Act, 2013. No financial impacts or other metrics were disclosed in the filing.

• ·Order pertains to amalgamation involving shareholders and creditors of both companies.
• ·NCLT: Ahmedabad bench.

09-03-2026

Battalion Oil Corporation entered into a definitive agreement to raise approximately $15 million gross ($14.1 million net after fees) through a private placement of common stock at $5.50 per share and/or prefunded warrants with a new institutional investor, with Roth Capital Partners as sole placement agent. The offering is expected to close on March 4, 2026, subject to customary conditions, with proceeds intended for working capital and general corporate purposes. The company also noted an increase in average oil production of approximately 1,200 net barrels per day in January compared to December.

• ·Expected closing date: March 4, 2026, subject to customary conditions
• ·Company to file resale registration statement on Form S-3 within 20 days of closing
• ·Securities offered in unregistered private placement under Securities Act exemptions
• ·Oil production increase of approximately 1,200 net barrels per day (January vs. December)

09-03-2026

Bunker Hill Mining Corp. closed a brokered LIFE offering of 150,808,332 units at C$0.18 for gross proceeds of C$27,145,500, a concurrent non-brokered private placement of 8,926,668 units for C$1,606,800, and a warrant exercise for C$5,000,000, totaling C$33,752,300 in aggregate proceeds. Net proceeds will fund working capital for the ramp-up of the Bunker Hill Mine to commercial production, exploration, and general corporate purposes. No declines or flat metrics reported; however, the offering involves dilution to existing shareholders and includes minor insider participation of 300,000 units.

• ·Each LIFE Unit includes one Common Share and one Warrant exercisable at C$0.30 for 36 months.
• ·Compensation Options exercisable at C$0.18 for 24 months.
• ·Insider participation relied on exemptions under MI 61-101.
• ·LIFE Units subject to 6-month U.S. hold period; registration statement to be filed within 5 business days.
• ·Announcement date: March 5, 2026; reverse split news releases: February 9, 2026 and March 3, 2026.

09-03-2026

Israel Acquisitions Corp amended its Form 8-K to disclose a waiver of administrative services fees to its Sponsor, including $240,000 accrued and $10,000 monthly fees until business combination or liquidation, aiding cash preservation. The filing also reveals a second amendment to the January 26, 2025 Business Combination Agreement with Gadfin Ltd. and Gadfin Regev Holdings Ltd., extending the termination date to March 16, 2026 while removing prior automatic extensions. These updates indicate ongoing efforts to complete the merger amid delays.

• ·Original BCA dated January 26, 2025; first amendment July 2, 2025
• ·Class A ordinary shares par value $0.0001; warrants exercise price $11.50 per share
• ·Securities trade on OTC Markets: ISLUF (units), ISRLF (shares), ISLWF (warrants)

09-03-2026

Cartesian Therapeutics reported total revenues of $2.8M for 2025, down 93% YoY from $38.9M, primarily due to a 99% drop in collaboration and license revenue to $0.4M, though grant revenue increased significantly to $2.4M. Operating expenses surged 77% to $146.2M, driven by a $56.7M impairment charge on the Descartes-08 for SLE intangible asset (up from $7.6M), R&D expenses up 29% to $58.0M, and G&A up 4% to $31.5M, resulting in a widened net loss of $130.3M (68% worse) and basic EPS of ($5.02). Cash and equivalents declined to $125.1M from $212.6M, with net cash decrease of $87.4M including $73.9M used in operations.

• ·In-process R&D assets declined to $93.9M from $150.6M as of Dec 31, 2025.
• ·Goodwill stable at $48.2M as of Dec 31, 2025.
• ·Stockholders’ deficit deepened to ($126.2M) from ($6.8M).
• ·Basic net loss per share ($5.02) vs ($4.48) YoY.
• ·CVR fair value loss of $4.4M in 2025.

09-03-2026

Alexander’s, Inc. (NYSE: ALX) entered into an agreement to sell its unencumbered Rego Park I property in Queens, New York, to Northwell Health, Inc., for a gross purchase price of $235.5M and net proceeds of $202M, expecting a financial statement gain of approximately $147M. The 338,000 sq ft vacant structure on 5.9 acres, built in 1959 with a 1,236-space parking garage, was recently vacated by relocating tenants to adjacent Rego Park II. The sale is subject to customary closing conditions and expected to close by Q3 2026.

• ·Rego Park I located at intersection of Queens Boulevard and Junction Boulevard, adjacent to Long Island Expressway
• ·Property built in 1959 as three-story vacant structure
• ·Tenants relocated to adjacent Rego Park II shopping center
• ·Contact phone: (201) 587-8541

09-03-2026

enGene Holdings Inc. reported a widened net loss of $29.8M for the three months ended January 31, 2026, up 21% YoY from $24.6M, driven by increased R&D expenses ($22.3M, +11%) and G&A expenses ($8.9M, +35%), with operating cash use rising to $28.9M from $25.7M. However, the company raised $126.3M gross from a public offering and $23.2M from pre-funded warrants, plus $25M from a Second Amended Term Loan, boosting total assets to $337.1M (up 52% QoQ from $221.5M) and shareholders' equity to $281.5M (up 68% QoQ). Cash and equivalents declined to $36.6M amid heavy investments in marketable securities.

• ·Loss per share improved to $0.44 from $0.48 YoY due to increased share count.
• ·Weighted-average shares outstanding: 67.3M in 2026 vs 51.0M in 2025.
• ·Marketable securities short-term increased to $239.3M from $143.6M QoQ.

09-03-2026

Boundless Bio reported Q4 and FY 2025 financial results with reduced R&D expenses (Q4: $9.8M vs $13.3M YoY, -26%; FY: $44.8M vs $55.3M, -19%) and net losses (Q4: $12.9M vs $16.4M, -21%; FY: $58.2M vs $65.4M, -11%), alongside a $108M cash position providing runway into H2 2028. The company opened enrollment in the KOMODO-1 trial for BBI-940 after FDA IND acceptance, but announced cessation of enrollment in the POTENTIATE trial of BBI-355 and BBI-825 due to prioritization. Cash decreased to $107.6M from $152.1M at end-2024.

• ·Total operating expenses Q4 2025: $14.0M vs $18.3M Q4 2024 (-23%)
• ·Total operating expenses FY 2025: $63.6M vs $73.3M FY 2024 (-13%)
• ·Net loss per share FY 2025: $(2.60) vs $(3.85) FY 2024
• ·Accumulated deficit as of Dec 31, 2025: $259.7M (up from $201.5M at end-2024)
• ·Working capital as of Dec 31, 2025: $97.1M (down from $146.3M at end-2024)

09-03-2026

Fluor Corporation's Executive Chairman David E. Constable announced his retirement effective May 6, 2026, coinciding with the annual stockholders' meeting, with James T. Hackett appointed as the new Board Chair effective May 5, 2026. The company entered a one-year consulting agreement with Constable for $525,200, payable quarterly starting May 6, 2026. The Board also expanded to 12 members and elected independent director Robert G. Card, assigning him to the Audit Committee and Commercial Strategies and Operational Risk Committee.

• ·Board elected Robert G. Card effective March 4, 2026; determined independent under NYSE standards.
• ·Consulting agreement dated March 4, 2026; full text to be filed in Q1 2026 10-Q.
• ·Annual stockholders' meeting scheduled for May 6, 2026.

09-03-2026

Ionis Pharmaceuticals announced that long-serving directors B. Lynne Parshall (since September 2000) and Joseph Wender (since January 1994, lead independent director since 2020) will retire at the end of their terms on June 4, 2026. Peter N. Reikes will rejoin the Board effective the same date, bringing expertise from recent roles at ARPA-H and FDA, as well as prior investment banking positions at Stifel, Cowen, and PaineWebber. The changes reflect planned transitions amid the company's growth, with no immediate disruptions noted.

• ·Parshall served as COO (Dec 2007-Dec 2017) and CFO (Jun 1994-Dec 2012)
• ·Wender joined Goldman Sachs in 1971, general partner in 1982, senior consultant since Jan 2008
• ·Reikes: Senior strategy advisor at ARPA-H (Dec 2024-Feb 2026), FDA senior advisor (prior 3+ years), previously Ionis director (2018-2021)
• ·Reikes education: B.A. Economics (UCLA), M.B.A. Finance (Wharton)